Boehringer Ingelheim (BI) and Eli Lilly and Company have partnered in an academic collaboration with the University of Oxford to investigate the effects of the companies’ diabetes drug, Jardiance (empagliflozin), on the progression of kidney disease and the occurrence of cardiovascular death.

The trial, EMPA-KIDNEY, will be independently conducted, analyzed, and reported by the Medical Research Council Population Health Research Unit at the University of Oxford, which is based in the Clinical Trial Service Unit and Epidemiological Studies Unit, in partnership with the Duke Clinical Research Institute. Boehringer Ingelheim and Lilly will provide the funding for the study.

EMPA-KIDNEY will include approximately 5,000 adults with established chronic kidney disease, with and without diabetes. The primary outcome of the study is to assess the effect of Jardiance on time to clinically relevant kidney disease progression or cardiovascular death. The study will be part of the empagliflozin clinical development program.

Source: Eli Lilly and Company and Boehringer Ingelheim